Austin Retina Associates

Austin, Texas 78705-1169

6 studies enrolling now · 82 studies all time

What they study most

Age - Related Macular Degeneration (AMD), Age-Related Macular Degeneration, Age-related Macular Degeneration (AMD), Anterior Uveitis, Branch Retinal Vein Occlusion, Central Retinal Artery Occlusion, Central Retinal Vein Occlusion, Choroidal Melanoma, Choroidal Neovascularization, Diabetes Mellitus, Diabetic Macular Edema, Diabetic Retinopathy

Studies at this site

• A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema — Recruiting now
• Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants — Recruiting now
• Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy — Recruiting now
• Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD — Recruiting now
• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) — Recruiting now
• Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study — Recruiting now
• A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio — Recruiting now
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 — Running, not enrolling
• A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma — Running, not enrolling
• Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease — Completed
• A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy — Running, not enrolling
• Fenofibrate for Prevention of DR Worsening — Running, not enrolling
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema — Completed
• An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration — Running, not enrolling
• 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration — Running, not enrolling
• Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) — Running, not enrolling
• Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy — Completed
• A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) — Running, not enrolling
• Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial — Running, not enrolling
• Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) — Completed
• Safety and Efficacy of Faricimab in Patients With NPDR — Completed
• A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe — Completed
• A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) — Running, not enrolling
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
• A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) — Completed
• Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy — Completed
• A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) — Completed
• Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — Running, not enrolling
• Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME — Running, not enrolling
• Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema — Completed
• A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) — Stopped early
• A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) — Stopped early
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion — Completed
• A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. — Stopped early
• A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) — Completed
• A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) — Completed
• Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy — Status unconfirmed
• DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME — Completed
• A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) — Stopped early
• A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema — Completed
• Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD — Completed
• A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD — Completed
• The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) — Completed